Ascendis Pharma A/S (NASDAQ:ASND) Given Average Rating of “Moderate Buy” by Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $195.92.

ASND has been the subject of several recent analyst reports. Bank of America raised their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Jefferies Financial Group raised their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. JPMorgan Chase & Co. dropped their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, September 16th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Private Ocean LLC bought a new position in Ascendis Pharma A/S in the first quarter worth about $36,000. Signaturefd LLC lifted its holdings in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the last quarter. Bessemer Group Inc. boosted its position in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 332 shares during the period. Pursue Wealth Partners LLC bought a new position in Ascendis Pharma A/S during the 3rd quarter worth $217,000. Finally, Searle & CO. acquired a new stake in Ascendis Pharma A/S in the second quarter worth $205,000.

Ascendis Pharma A/S Stock Down 3.1 %

Shares of NASDAQ:ASND opened at $122.80 on Friday. The company has a market capitalization of $7.15 billion, a price-to-earnings ratio of -12.78 and a beta of 0.64. The company has a 50 day moving average of $134.04 and a two-hundred day moving average of $133.89. Ascendis Pharma A/S has a 52-week low of $86.54 and a 52-week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, equities analysts anticipate that Ascendis Pharma A/S will post -7.2 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.